<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03912987</url>
  </required_header>
  <id_info>
    <org_study_id>20180908</org_study_id>
    <secondary_id>U01NS107027</secondary_id>
    <nct_id>NCT03912987</nct_id>
  </id_info>
  <brief_title>TRIAL READY (Clinical Trial Readiness)</brief_title>
  <official_title>TRIAL READY (Clinical Trial Readiness)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study, being conducted under the auspice of the CReATe Consortium, will enroll patients&#xD;
      with ALS and related disorders as well as healthy controls, with the goal of facilitating&#xD;
      clinical validation of leading biological-fluid based biomarker candidates that may aid&#xD;
      therapy development for patients with ALS and related disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-center study aims to clinically validate leading biological-fluid-based biomarker&#xD;
      candidates as potential prognostic and pharmacodynamic biomarkers that have the potential to&#xD;
      facilitate therapy development for patients with ALS and related disorders. Biomarker&#xD;
      candidates that will be considered include: urinary p75 neurotrophin receptor extracellular&#xD;
      domain (p75ECD), blood and cerebrospinal fluid (CSF) phosphorylated neurofilament heavy&#xD;
      (pNfH), blood and CSF neurofilament light (NfL) and, in the population with a C9orf72&#xD;
      hexanucleotide repeat expansion, peripheral blood mononuclear cell (PBMC) and CSF levels of&#xD;
      the dipeptide repeat protein poly(GP). In pursuit of these goals, the CReATe Consortium is&#xD;
      already collecting longitudinal biological samples from patients with ALS and related&#xD;
      disorders through the ongoing Phenotype-Genotype-Biomarker (PGB) study. TRIAL READY aims to&#xD;
      identify additional patients with the C9orf72 hexanucleotide repeat expansion mutation&#xD;
      (HREM), the most common genetic cause of ALS, who may be further followed through the PGB&#xD;
      study. This study will also enroll and longitudinally evaluate a cohort of age- and&#xD;
      gender-match healthy controls.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2019</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Longitudinal trajectories (and variability) of leading biological-fluid biomarker candidates.</measure>
    <time_frame>12 months</time_frame>
    <description>In a population of patients with ALS and related disorders who would meet typical clinical trial eligibility, this study aims to define the natural history (and variability) of urinary neurotrophin receptor extracellular domain (p75ECD); blood and cerebrospinal fluid (CSF) neurofilament light (NfL) and phosphorylated neurofilament heavy (pNfH); and among patients with the C9orf72 hexanucleotide repeat expansion mutation (HREM), CSF and peripheral blood mononuclear cell (PBMC) poly(GP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prognostic utility of leading biological-fluid biomarker candidates.</measure>
    <time_frame>12 months</time_frame>
    <description>In a population of patients with ALS and related disorders who would meet typical clinical trial eligibility, quantify the prognostic value that baseline biomarker levels add to readily available clinical factors that are known to predict prognosis.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">610</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Frontotemporal Dementia</condition>
  <condition>ALS-Frontotemporal Dementia</condition>
  <condition>Primary Lateral Sclerosis</condition>
  <condition>Progressive Muscular Atrophy</condition>
  <arm_group>
    <arm_group_label>Affected</arm_group_label>
    <description>Affected with ALS or a related disorder, including ALS-FTD, FTD, PLS, and PMA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>Those never diagnosed with and not at particular risk for developing ALS or a related disorder.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA, serum, plasma, buffy coat, urine and CSF&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ALS or a related neurodegenerative disorder, including FTD, ALS-FTD, PLS and&#xD;
        PMA. Individuals never diagnosed with and not at particular risk of developing ALS or a&#xD;
        related disorder.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Member of at least one of the following categories:&#xD;
&#xD;
               1. Individuals with a clinical diagnosis of ALS or a related disorder, including&#xD;
                  FTD, ALS-FTD, PLS, and PMA.&#xD;
&#xD;
               2. Individuals never diagnosed with and not at particular risk of developing ALS or&#xD;
                  a related disorder.&#xD;
&#xD;
          -  Able and willing to comply with relevant procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A condition or situation which, in the PI's opinion, could confound the study finding&#xD;
             or may interfere significantly with the individual's participation and compliance with&#xD;
             the study protocol. This includes (but is not limited to) neurological, psychological&#xD;
             and/or medical conditions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Benatar</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Benatar, MBChB, MS, DPhil</last_name>
    <phone>305-243-4015</phone>
    <email>projectcreate@med.miami.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Cooley</last_name>
    <phone>844-837-1031</phone>
    <email>projectcreate@med.miami.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Hernandez</last_name>
      <phone>305-243-2345</phone>
      <email>projectcreate@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Benatar, MBChB, MS, DPhil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Collin Gerringer</last_name>
      <phone>913-574-0008</phone>
      <email>cgerringer@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Statland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Rosario</last_name>
      <phone>215-898-3081</phone>
      <email>luis.rosario@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Corey McMillan, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 27, 2019</study_first_submitted>
  <study_first_submitted_qc>April 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2019</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Michael Benatar</investigator_full_name>
    <investigator_title>Chief, Neuromuscular Division</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

